Beamion Lung 1: Zongertinib (BI 1810631) in Advanced HER2+ NSCLC
January 12th 2024
Edgardo Santos, MD, FACP, FCCP, provides insights into the innovative Beamion Lung 1 trial, focused on assessing the safety and tolerability of zongertinib (BI 1810631) in patients with advanced, previously treated HER2+ non-small cell lung cancer (NSCLC).